Publications by authors named "Anne Messer"

Claim this Profile
E
ENGINEERED NANOBODIES WITH PROGRAMMABLE TARGET ANTIGEN PROTEOLYSIS (PTAP) FUSIONS REGULATE INTRACELLULAR ALPHA-SYNUCLEIN IN VITRO AND IN VIVO.
Diptaman Chatterjee, Lianna Y D'Brant, Benjamin M Hiller, David J Marmion, Ivette M Sandoval, Anne Messer

Res Sq· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9.
Diptaman Chatterjee, David J Marmion, Jodi L McBride, Fredric P Manfredsson, David Butler, Anne Messer

Gene Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders.
Anne Messer, David C Butler

Neurobiol Dis· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulation.
Arlene I Ramsingh, Steven J Gray, Andrew Reilly, Michael Koday, Debbie Bratt, Anne Messer

PLoS One· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational affinity maturation of camelid single-domain intrabodies against the nonamyloid component of alpha-synuclein.
Sai Pooja Mahajan, Bunyarit Meksiriporn, Dujduan Waraho-Zhmayev, Kevin B Weyant, Ilkay Kocer, Anne Messer

Sci Rep· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulation.
Arlene I Ramsingh, Steven J Gray, Andrew Reilly, Michael Koday, Debbie Bratt, Anne Messer

PLoS One· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model.
Diptaman Chatterjee, Mansi Bhatt, David Butler, Erwin De Genst, Christopher M Dobson, Anne Messer

NPJ Parkinsons Dis· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA.
James W Larrick, Mark R Alfenito, Jamie K Scott, Paul W H I Parren, Dennis R Burton, Anne Messer

MAbs· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
David C Butler, Shubhada N Joshi, Erwin De Genst, Ankit S Baghel, Christopher M Dobson, Anne Messer

PLoS One· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's disease.
Arlene I Ramsingh, Kevin Manley, Yinghui Rong, Andrew Reilly, Anne Messer

Hum Mol Genet· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure of a single-chain Fv bound to the 17 N-terminal residues of huntingtin provides insights into pathogenic amyloid formation and suppression.
Erwin De Genst, Dimitri Y Chirgadze, Fabrice A C Klein, David C Butler, Dijana Matak-Vinković, Anne Messer

J Mol Biol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibodies and protein misfolding: From structural research tools to therapeutic strategies.
Erwin De Genst, Anne Messer, Christopher M Dobson

Biochim Biophys Acta· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineered antibody therapies coming of age for aging brains.
Anne Messer

Mol Ther· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughts.
Mansi A Bhatt, Anne Messer, Jeffrey H Kordower

J Parkinsons Dis· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies.
Shubhada N Joshi, David C Butler, Anne Messer

MAbs· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrabodies as neuroprotective therapeutics.
Anne Messer, Shubhada N Joshi

Neurotherapeutics· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MSH3 polymorphisms and protein levels affect CAG repeat instability in Huntington's disease mice.
Stéphanie Tomé, Kevin Manley, Jodie P Simard, Greg W Clark, Meghan M Slean, Anne Messer

PLoS Genet· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.
David C Butler, Julie A McLear, Anne Messer

Prog Neurobiol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.
David C Butler, Anne Messer

PLoS One· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.
Tyisha Hathorn, Abigail Snyder-Keller, Anne Messer

Neurobiol Dis· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice.
Abigail Snyder-Keller, Julie A McLear, Tyisha Hathorn, Anne Messer

J Neuropathol Exp Neurol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mini-review: polybrominated diphenyl ether (PBDE) flame retardants as potential autism risk factors.
Anne Messer

Physiol Behav· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.
Erik Kvam, Michael R Sierks, Charles B Shoemaker, Anne Messer

Protein Eng Des Sel· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing intrabodies for the therapeutic suppression of neurodegenerative pathology.
Anne Messer, Sandra M Lynch, David C Butler

Expert Opin Biol Ther· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.
Erik Kvam, Brent L Nannenga, Min S Wang, Zongjian Jia, Michael R Sierks, Anne Messer

PLoS One· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis